MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock upon...
$544,194K
Proceeds from stock
options exercised
$20,995K
Net cash provided by
financing activities
$564,603K
Effect of exchange rate
changes on cash and cash...
$377K
Canceled cashflow
$586K
Net change in cash
and cash...
$472,655K
Canceled cashflow
$92,325K
Payment of offering
costs
$586K
Stock-based compensation
$12,715K
Prepaid expenses and
other current assets
-$2,869K
Accounts payable
$1,563K
Accrued expenses and
other current...
$756K
Accounts receivable
-$319K
Depreciation on property and
equipment
$101K
Non-cash lease expense
$25K
Net cash used in
operating activities
-$92,325K
Canceled cashflow
$18,348K
Net loss
-$110,635K
Other assets
$38K
Back
Back
Cash Flow
source: myfinsight.com
Immunovant, Inc. (IMVT)
Immunovant, Inc. (IMVT)